Archive · 2026 · October 2026

Daily digest — 2026-10-20

2026-10-20

Five science items today: PROTAC target engagement reinterpreted through intracellular exposure, a CNS-penetrant PARP1-selective inhibitor, covalent epoxysuccinate PLpro inhibitors, an AlphaLISA screen for ISG15–UBA7, and kinase-inhibitor protonation states. Business: Gilead's oral UC data and Merck KGaA buying Silence.

⚗️

Medicinal Chemistry

4 articles

Epoxysuccinamide warheads hit SARS-CoV-2 PLpro hard, but a hydrazide linker undermines them

  • Covalent PLpro inhibitors were designed by combining an epoxysuccinamide warhead for Cys-111 with groove-binding features borrowed from non-covalent inhibitors.
  • The compounds showed very high enzymatic potency and strongly reduced viral titres in cell culture.
  • The flexible hydrazide linker was cleaved by hepatic carboxylesterases, and alternative linkers did not work, so the series is metabolically limited.
💡 Points

A potent warhead that dies in the liver is a familiar story, and here the culprit is the very linker the chemistry needs for Cys-111 reach. I'd still keep the epoxysuccinamide in the toolbox for the next coronavirus, but the linker would be the first thing I'd redesign.

Discovery of Epoxysuccinates as Potent Covalent Inhibitors of SARS-CoV-2 Papain-like Protease ↗

Replacing saruparib's carboxamide yields an oral, brain-penetrant PARP1-selective inhibitor

  • Aimed at CNS malignancies, the program replaced the carboxamide of saruparib with a series of heterocycles, targeting PARP1 over PARP2 to limit haematological toxicity.
  • Caco-2 efflux, rather than the usual MDR1-MDCK assay, was used as a progression filter to select compounds with good unbound brain exposure.
  • The lead compound was orally bioavailable and caused tumour regression in xenografts at a low dose, with a projected low clinical dose.
💡 Points

Swapping the primary carboxamide is a bold move, since that group anchors the nicotinamide pocket, and the heterocycles evidently kept the binding. The more useful lesson is the filter: if Caco-2 efflux predicts unbound brain exposure better than MDR1-MDCK, plenty of CNS programs may be discarding good compounds.

Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors ↗

Much of the PROTAC target-engagement spread is exposure, not E3 recognition

  • Twenty PROTACs with varied E3 ligands, linkers and target binders were profiled in intracellular NanoBRET competition assays against cereblon and VHL tracers.
  • Apparent potency spread widely when referenced to applied concentration, and passive Caco-2 permeability explained little of it.
  • Correcting for measured intracellular unbound exposure shrank the spread dramatically, matching values from permeabilized cells.
💡 Points

Before I read a PROTAC SAR table as E3 affinity, I'd now ask what the cell actually saw. If most of the shift is unbound exposure, linker tweaks that look like potency gains may just be permeability gains, and measuring exposure early keeps us from chasing the wrong variable.

Exploring the Relationship between Cell Permeability, Intracellular Exposure, and Target Engagement for PROTACs ↗

An AlphaLISA screen opens the ISG15–UBA7 interaction to inhibitor hunting

  • ISG15 and its E1 enzyme UBA7 drive ISGylation, a pathway linked to treatment resistance in cancer, yet no inhibitors exist.
  • The authors built an AlphaLISA assay for the ISG15–UBA7 interaction with strong robustness metrics for high-throughput use.
  • A pilot screen of a small library gave a handful of hits, two of which also reduced ISGylation in cells.
💡 Points

This is a pilot on under a thousand compounds, so the hits are starting points, not leads. What matters is that a protein-protein interaction between a ubiquitin-like modifier and its E1 now has a screenable format. I'd run it against a real diversity set and counter-screen AlphaLISA interferers hard.

A High-Throughput Screening Platform for the Discovery of Noncovalent Inhibitors of the ISG15–UBA7 Interaction ↗

💻

Computational & AI

1 article

Kinase inhibitors often change protonation or tautomer state on binding, MCCE modelling shows

  • Multi-conformation continuum electrostatics was applied to 37 co-crystal structures of nine kinase domains with 18 approved inhibitors.
  • Protein net charge stayed largely stable on binding, whereas inhibitor charge states frequently shifted up or down.
  • Binding can resolve two near-equal solution tautomers into one, creating free-energy differences of a few kcal/mol.
💡 Points

Docking with one fixed protonation state is quietly baked into most of our virtual screening, and this says it can be wrong by kcal/mol for approved drugs. When a scaffold with a tautomerisable heterocycle misbehaves in SAR, I'd now check its bound-state tautomer before blaming the pocket.

Kinase Inhibitors can Change Protonation or Tautomeric State upon Binding ↗

🏢

Industry News

2 articles

Gilead's oral emvistegrast meets the primary endpoint in Phase 2 ulcerative colitis

  • Gilead's once-daily oral α4β7 integrin inhibitor emvistegrast (GS-1427) met its primary endpoint in the Phase 2 SWIFT study in ulcerative colitis.
  • At the 200 mg dose, clinical remission at week 12 was roughly three times the placebo rate, with nominal significance and good tolerability.
  • STAT's report is paywalled; figures here follow Gilead's own statement.
💡 Points

An oral α4β7 blocker is the obvious answer to injectable vedolizumab, and a roughly 23-point placebo-adjusted remission is credible for a Phase 2. But the p-values are nominal and the arms are small, so Phase 3 and Takeda's entrenched biologic franchise, not this readout, decide whether the oral convenience story pays.

Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds ↗

Merck KGaA buys Silence Therapeutics for about $1.3B after siRNA Phase 2 win

  • Merck KGaA will acquire Silence in an all-cash deal at $20 per ADS, an equity value of about $1.3 billion, via a UK scheme of arrangement.
  • The price is a 130% premium to the prior close, and Silence called it the outcome of a competitive sale process.
  • The deal follows positive Phase 2 data for Silence's siRNA divesiran in polycythemia vera.
💡 Points

A 130% premium for a single mid-stage asset says Merck KGaA is paying for de-risked rare-haematology data and a validated platform, not for breadth. It needs growth after its portfolio gaps, and siRNA offers a modality it can slot in. Watch whether Silence's platform survives as a standalone engine or just feeds divesiran.

Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win ↗